학술논문

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.
Document Type
Article
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe14597-e14597, 1p
Subject
Language
ISSN
0732183X